Icad Inc Stock Price, News & Analysis

iCAD, a leader in cancer detection and therapy, will have its CEO, Michael Klein, participate in a fireside chat at the BTIG Virtual MedTech Conference on February 18 at 4:30 PM ET. This event will allow Klein to discuss the company's innovative technologies, including ProFound AI, which enhances mammography efficiency and accuracy. Investors can access the live presentation through the company's website. iCAD is also known for the Xoft System, which offers targeted cancer treatment while preserving healthy tissue.

NASHUA, N.H., Jan. 19, 2021 -- iCAD, a leader in medical technology focused on cancer detection, announced that CEO Michael Klein will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 20 at 11:00 AM ET. Klein will also hold one-on-one meetings with investors. A live audio webcast of the presentation will be accessible on iCAD's investor website, with a replay available afterward. iCAD is known for its ProFound AI and Xoft System, innovative solutions aimed at improving cancer treatment and detection.

iCAD announced its participation in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021. CEO Michael Klein will host meetings and participate in a panel titled Innovations in Cancer Diagnostics on January 7 at 4pm EST. The focus will be on the newly launched ProFound AI Risk software, which provides a 2-year risk estimation for breast cancer based solely on screening mammograms. Research indicates this tool effectively identifies women at high risk of a breast cancer diagnosis within two years.

iCAD, a leader in cancer detection and therapy, has appointed Dr. Santosh Kesari as Principal Investigator for an international multi-center clinical trial. The trial will evaluate the Xoft Axxent Electronic Brachytherapy System as a sole treatment for recurrent glioblastoma (GBM) following surgery. Commencing in January 2021, it aims to enroll 80-100 participants. The Xoft System delivers precise radiation to the tumor site, minimizing harm to surrounding tissue. Results may lead to quicker adoption of this innovative therapy, addressing a critical need in the aggressive treatment of GBM.

iCAD and Solis Mammography have entered a five-year partnership to integrate iCAD's ProFound AI technology across Solis's extensive network, enhancing breast cancer detection. The ProFound AI platform aims to improve patient outcomes for over one million women served, utilizing advanced AI for precise cancer risk estimation. This collaboration underscores iCAD's commitment to women's health, as it offers a clinically proven increase in mammography reading accuracy and reduced false positives. Both companies are positioned for growth in the evolving healthcare landscape.

iCAD has announced a webinar on December 7, 2020, featuring leading experts discussing its ProFound AI Risk, a novel breast cancer risk assessment tool. This innovative solution shifts the focus from age-based to risk-adaptive screening. The tool has shown promise in identifying women at high risk of breast cancer within two years of a negative mammogram, as highlighted in recent research published in Radiology. The webinar will also cover advancements in iCAD's ProFound AI technology platform for digital breast tomosynthesis, aiming to enhance cancer detection.

iCAD has introduced the ProFound AI Risk, a groundbreaking tool that enhances breast cancer screening by transitioning from an age-based to a risk-adapted approach. Showcased at the RSNA annual meeting, this innovation offers a precise two-year breast cancer risk estimation based solely on screening mammograms. Developed in collaboration with the Karolinska Institutet, it significantly outperforms existing risk models. The technology is expected to enhance patient care, reduce reading time for radiologists by 52.7%, and improve detection rates.

iCAD announces new clinical data supporting the Xoft Axxent Electronic Brachytherapy System presented at the ESTRO 2020 meeting.

The studies affirm the system's efficacy in treating early-stage breast and endometrial cancers, showcasing its viability as an alternative to traditional methods. Key findings highlight significant radiation dose reductions to adjacent organs, enhancing patient safety. Since 2015, over 600 early-stage breast cancer and 150 gynecological cancer patients have been treated using the Xoft system, which is FDA-cleared and CE-marked for multiple cancer types.

iCAD, Inc. (NASDAQ: ICAD) has reported significant sales momentum for its ProFound AI® software, with over 1,000 licenses sold since launch, demonstrating widespread adoption across major mammography vendors including GE and Siemens. The Company achieved a 44% sequential revenue growth in Q3 2020 due to increased demand for its breast health AI solutions. Notably, ProFound AI for DBT showcases highest cancer detection rates and a remarkable 52.7% reduction in radiologists' reading time. Additionally, iCAD expanded its international market presence with agreements in Switzerland and Portugal.